Manufacturer sources
Beacon Pharmaceuticals’ official Tagrix product page identifies the product, generic name, formulation, pack size and 80 mg strength.
Beacon’s published prescribing information provides composition, pharmacology, dosage, dose modification, interactions, storage and manufacturing information.
Regulatory sources
The EMA provides official information on TAGRISSO, including its indications, EGFR testing and treatment supervision.
FDA information documents approvals for osimertinib in additional EGFR-mutated NSCLC settings, including combination chemotherapy and unresectable stage III disease.
Biomarker sources
FDA companion-diagnostic documentation supports the clinical importance of EGFR exon 19 deletion, L858R and T790M testing for relevant osimertinib treatment decisions.
Manufacturer quality information
Beacon publishes information about its quality-management systems and manufacturing standards.